OVATION SCIENCE INC.

Condensed Consolidated Interim Financial Statements

For the Three and Nine Months Ended September 30, 2021 and 2020

Expressed in Canadian dollars
(Unaudited)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements for Ovation Science Inc. (the "Company") have been prepared by management in accordance with International Financing Reporting Standards ("IFRS"). These condensed consolidated interim financial statements, which are the responsibility of management, are unaudited and have not been reviewed by the Company's auditors. The Company's Audit Committee and Board of Directors have reviewed and approved these condensed consolidated interim financial statements. In accordance with the disclosure requirements of National Instrument 51-102 released by the Canadian Securities Administrators, the Company's independent auditors have not performed a review of these condensed consolidated interim financial statements.

OVATION SCIENCE INC.
Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian dollars)
(Unaudited)

	Notes		As at September 30, 2021		As at December 31, 2020
ASSETS					
Current assets					
Cash		$	**870,188**	$	380,621
Short-term investment	3		**-**		1,157,575
Trade and other receivables	4		**60,129**		49,935
Prepaid expenses	5		**16,066**		15,281
Inventory	6		**851,956**		886,404
			1,798,339		2,489,816
Licenses	7		**741,995**		741,995
Furniture and equipment	8		**13,788**		19,922
Total assets		$	**2,554,122**	$	3,251,733
LIABILITIES AND SHAREHOLDERS' EQUITY					
Current liabilities					
Accounts payable and other liabilities	9, 13	$	**44,713**	$	143,383
Total liabilities			**44,713**		143,383
Shareholders' equity					
Share capital	10		**4,280,458**		4,280,458
Reserves	11		**1,398,848**		1,398,848
Accumulated other comprehensive income			**(10,453)**		19,806
Deficit			**(3,159,444)**		(2,590,762)
Total shareholders' equity			**2,509,409**		3,108,350
Total liabilities and shareholders' equity		$	**2,554,122**	$	3,251,733

Nature of business and going concern (Note 1)

These condensed consolidated interim financial statements were approved by the Board of Directors on November 26, 2021:

"Logan Anderson" Director *"Terry Howlett"* Director

OVATION SCIENCE INC.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Expressed in Canadian dollars)
(Unaudited)

	Note		Three months ended September 30, 2021	Three months ended September 30, 2020		Nine months ended September 30, 2021	Nine months ended September 30, 2020
Revenue							
Product sales	12	**$**	**22,705**	74,050	**$**	**80,588**	423,919
Royalty fees			**12,140**	106,944		**89,089**	189,238
Research			**50**	-		**15,014**	-
			34,895	180,994		**184,691**	613,157
Cost of sales	6		**(2,521)**	(38,816)		**(37,804)**	(186,787)
Gross margin			**32,374**	142,178		**146,887**	426,370
Operating expenses							
Advertising and promotion			**3,223**	-		**24,398**	-
Depreciation	8		**2,031**	2,149		**5,989**	6,503
Investor relations			**31,819**	62,948		**116,092**	147,393
Management and director fees	13		**89,497**	95,832		**271,050**	285,252
Office and general			**65,203**	87,293		**181,866**	187,824
Product development			**17,434**	28,448		**43,500**	132,723
Professional fees			**26,282**	56,661		**81,857**	143,767
Royalty fees			**60**	11,402		**4,824**	21,557
Share-based payments	11		**-**	-		**-**	387,820
			235,549	344,733		**729,576**	1,312,839
Loss from operations			**(203,175)**	(202,555)		**(582,689)**	(886,469)
Other income (expenses)							
Interest expense			**-**	(3,696)		**-**	(15,675)
Interest income	3		**2**	3,736		**4,789**	10,071
Change in fair value of derivative liability			**-**	-		**-**	-
Foreign exchange gain (loss)			**567**	2,333		**9,218**	(18,676)
Gain on expiration of conversion options			**-**	-		**-**	11,781
Loss on debt settlement			**-**	(53,646)		**-**	(53,646)
Net loss		**$**	**(202,606)**	(253,828)	$	**(568,682)**	(952,614)
Foreign currency translation to reporting currency			**5,513**	(1,314)		**(30,259)**	9,871
Net loss and comprehensive loss		$	**(197,093)**	(255,142)	$	**(598,941)**	(942,743)
Loss per share – basic and diluted		$	**(0.01)**	(0.01)	$	**(0.02)**	(0.04)
Basic and diluted weighted average number of common shares outstanding			**29,374,836**	25,256,902		**29,374,836**	24,246,096

The accompany notes are an integral part of these condensed consolidated interim financial statements

OVATION SCIENCE INC.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Expressed in Canadian dollars)
(Unaudited)

	Share capital										
	Number		Amount		Reserves		Accumulated Other Comprehensive Loss		Deficit		Total shareholders' equity
Balance at December 31, 2019	**23,234,631**	**$**	**1,940,692**	**$**	**941,198**	**$**	**1,597**	**$**	**(1,405,888)**	**$**	**1,477,599**
Shares issued for cash	5,040,000		2,116,800		-		-		-		2,116,800
Share issuance costs	-		(269,782)		121,606		-		-		(148,176)
Options exercised	350,000		143,871		(38,871)		-		-		105,000
Warrants exercised	213,750		134,295		(38,107)		-		-		96,188
Shares issued for debt settlement	536,455		214,582		-		-		-		214,582
Share-based payments	-		-		387,820		-		-		387,820
Foreign currency translation adjustment	-		-		-		8,274		-		8,274
Loss for the period	-		-		-		-		(952,614)		(952,614)
Balance at September 30, 2020	**29,374,836**	**$**	**4,280,458**	**$**	**1,373,646**	**$**	**9,871**	**$**	**(2,358,502)**	**$**	**3,305,473**
Balance at December 31, 2020	**29,374,836**		**4,280,458**		**1,398,848**		**19,806**		**(2,590,762)**		**3,108,350**
Foreign currency translation adjustment	-		-		-		(30,259)		-		(30,259)
Loss for the period	-		-		-		-		(568,682)		(568,682)
Balance at September 30, 2021	**29,374,836**	**$**	**4,280,458**	**$**	**1,398,848**	**$**	**(10,453)**	**$**	**(3,159,444)**	**$**	**2,509,409**

OVATION SCIENCE INC.
Condensed Consolidated Interim Statements of Cash Flows
(Expressed in Canadian dollars)
(Unaudited)

		Nine months ended September 30, 2021		Nine months ended September 30, 2020
OPERATING ACTIVITIES				
Net loss for the period	**$**	**(568,682)**	$	(952,614)
Adjustments for non-cash items:				
Interest expense		**-**		10,088
Share-based payments		**-**		387,820
Change in fair value of derivative liability		**-**		(11,781)
Interest earned		**-**		(5,651)
Depreciation expense		**5,989**		6,503
Loss on debt settlement		**-**		53,646
Changes in working capital items:				
Trade and other receivables		**(10,194)**		(112,028)
Inventory		**34,448**		(811,161)
Prepaid expense		**(785)**		40,508
Accounts payable and other liabilities		**(98,670)**		78,920
Cash flows used in operating activities		**(637,894)**		(1,315,750)
INVESTING ACTIVITIES				
Redemptions (purchases) of short-term investments		**1,157,575**		(900,000)
Intangibles		**-**		(135,183)
Cash flows (used in) provided by investing activities		**1,157,575**		(1,035,183)
FINANCING ACTIVITIES				
Repayment of related party loans		**-**		(68)
Repayment of promissory notes		**-**		(100,000)
Proceeds from issuance of shares		**-**		1,968,624
Proceeds from exercise of options		**-**		90,000
Proceeds from exercise of warrants		**-**		96,188
Cash flows provided by financing activities		**-**		2,054,744
Effect of foreign exchange		**(30,114)**		10,747
Change in cash		**489,567**		(285,442)
Cash, beginning		**380,621**		378,756
Cash, ending	$	**870,188**	$	93,314

Non-cash transactions:				
Repayment of promissory note through issuance of shares	$	**-**	$	15,000
Shares issued for debt settlement		**-**		160,936
Interest paid		**-**		5,520

1. NATURE OF BUSINESS AND GOING CONCERN

Ovation Science Inc. (the "Company") was incorporated in the Province of British Columbia on July 18, 2017, under the Business Corporations Act of British Columbia. The Company is in the business of providing topical and transdermal cannabis products under the "Ovation" brand label utilizing patented "Invisicare" delivery technology which it acquired for exclusive use for cannabis formulated products from Skinvisible Pharmaceuticals, Inc. ("Skinvisible"). On February 3, 2020, the Company acquired the exclusive world-wide rights to a DermSafe® Hand Sanitizer, the Company's first non-cannabis product. The Company's shares are traded on the Canadian Securities Exchange under the symbol "OVAT" and the US exchange OTCQB under the symbol "OVATF".

The Company's head office is located at Suite 1140 – 625 Howe Street, Vancouver, B.C. V6C 2T6, and its registered office is Suite 704, 595 Howe Street, Vancouver, B.C. V6C 2T5.

The Company's wholly owned subsidiary, Ovation Science USA Inc.'s operations are located in Las Vegas, Nevada. All Research and Development is conducted in the Company's own laboratory headed by its PhD. Chemist. Additionally, global sales and marketing are located in the US office.

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2021 the Company is not able to finance day to day activities through operations and has incurred losses since inception. The continuing operations of the Company are dependent upon its ability to develop a viable business and to attain profitable operations and generate funds there from. This indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs with loans from directors and companies controlled by directors and/or issuance of common shares. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its consolidated statements of financial position.

COVID-19
The recent outbreak of the coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Conditions surrounding the coronavirus continue to rapidly evolve and government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada, the United States. and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies followed by the Company are set out in Note 2 to the audited annual consolidated financial statements for the year ended December 31, 2020 and have been consistently followed in the preparation of these condensed consolidated interim financial statements. Except as summarized below, the Company used the same accounting policies and methods of computation as in the audited annual consolidated financial statements for the year ended December 31, 2020.

Basis of preparation

Statement of compliance
These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to the preparation of interim financial statements, including International Accounting Standards ("IAS") 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 26, 2021.

Basis of measurement
These condensed consolidated interim financial statements have been prepared on a historical cost basis, modified where applicable. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information. The condensed consolidated interim financial statements are presented in Canadian dollars, unless otherwise noted.

Basis of consolidation
These consolidated financial statements include the amounts of the Company and its wholly-owned subsidiary, Ovation Science USA Inc. All inter-company balances, transactions, income and expenses have been eliminated upon consolidation.

Subsidiaries are entities controlled by the Company. Control exists when the Company has power over an entity, when the Company is exposed, or has rights, to variable returns from the entity and when the Company has the ability to affect those returns through its power over the entity. Subsidiaries are included in the consolidated financial results of the Company from the effective date of acquisition up to the effective date of disposition or loss of control. Where necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with those used by the Company.

Significant estimates and judgments

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

In preparing these condensed consolidated interim financial statements, management has made judgments, estimates and assumptions that affect the applicable of the Company's accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

In preparing these condensed consolidated interim financial statements, the significant estimates and critical judgments were the same as those applied to the financial statements as at and for the year ended December 31, 2020.

Accounting standards issued but not yet effective

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company has not early adopted any new standards and determined that there are no standards that are relevant to the Company.

3. SHORT-TERM INVESTMENT

During the nine months ended September 30, 2021, the Company redeemed its guaranteed investment certificate ("GIC") of $1,150,000 (2020 - $600,000) and earned $4,783 (2020 - $10,071) in interest income.

As at December 31, 2020, short-term investments consist of a GIC of $1,150,000 which bore interest at 1.10% per annum and matured on May 27, 2021. As at December 31, 2020, the balance included interest receivable of $7,575.

(Expressed in Canadian dollars)

4. TRADE AND OTHER RECEIVABLES

		September 30, 2021		December 31, 2020
Trade receivables	$	49,506	$	46,838
GST receivable		10,623		3,097
	$	60,129	$	49,935

5. PREPAID EXPENSES

		September 30, 2021		December 31, 2020
Prepaid expenses	$	13,566	$	12,781
Legal retainer		2,500		2,500
	$	16,066	$	15,281

6. INVENTORY

		September 30, 2021		December 31, 2020
Finished goods	$	624,289	$	659,069
Packaging		153,276		152,359
Raw materials		74,391		74,976
	$	851,956	$	886,404

During the three and nine months ended September 30, 2021, the Company incurred $2,521 and $37,804 respectively (2020 - $38,816 and $186,787) in costs of sales related to inventory.

7. LICENSES

On September 29, 2017, the Company entered into a License and Assignment Agreement (the "Assignment Agreement") with Skinvisible, whereby Skinvisible granted the License to the Company. The agreement shall remain in effect, except for sub-licensees appointed by the Company. The consideration for the Assignment Agreement is US$500,000 ($606,812) payable as follows:

- $312,000 (US$250,000) within 90 days of execution of this agreement (paid);
- A promissory note for $294,812 (US$250,000) due upon the earlier of the Company completing an initial public offering or March 31, 2018, which was later amended to June 30, 2018 and September 15, 2018 (paid).

On November 10, 2017, the Company entered into a License Agreement (the "Agreement") with Lighthouse Strategies, LCC ("Lighthouse"), whereby the Company granted to Lighthouse the exclusive right to, utilize the License. The agreement shall remain in effect until terminated (with 30 days written notice from either party), unless failure to comply with the terms in the agreement. As part of the consideration related to this agreement, the Company has received a quarterly minimum packaging fee that started at the beginning of June 2018. On October 28, 2020, the Company amended the Lighthouse Agreement in a one-year agreement which makes CBD products non-exclusive and only THC products exclusive and limits their licensed territory to the state of Nevada.

On February 3, 2020, the Company entered into a License Agreement (the "License Agreement"), with Skinvisible, whereby Skinvisible granted the Company rights to Skinvisible's hand sanitizer with the brand name "DermSafe" or DermSafe PC ("DermSafe"). The License Agreement provides the Company with the right to extend the License and patent the DermSafe sanitizer by paying a renewal fee of $135,183 (US$100,000) in two payments over three and a half years from the date of the License Agreement.

(Expressed in Canadian dollars)

7. LICENSES (Continued)

On June 10, 2020, the Company entered into a License Renewal Agreement (the "Renewal Agreement") with Skinvisible, whereby Company shall accelerate the renewal payments to June 10, 2020, totaling $135,183 (US$100,000), in exchange for the DermSafe Health Canada Drug Identification numbers, trademarks, clinical data and certain rights to patent to the Company.

A continuity of the licenses is as follows:

As at December 31, 2019	**$**	**606,812**
Additions		135,183
As at December 31, 2020 and September 30, 2021	**$**	**741,995**

The key assumptions used in the calculations of the recoverable amounts include sales growth per year, changes in cost of sales and operating costs based on internal forecasts. Cash flows were projected out 5 years and a terminal value was calculated using a long-term steady growth of 13.4%. A pre-tax discount rate of 17.5% was used.

8. FURNITURE AND EQUIPMENT

		Furniture		Computer equipment		Total
Cost:						
At December 31, 2019	**$**	**15,619**	**$**	**15,619**	**$**	**31,238**
Additions		-		-		-
Foreign translation impact		(330)		(330)		(660)
At December 31, 2020	**$**	**15,289**	**$**	**15,289**	**$**	**30,578**
Foreign translation impact		(38)		(38)		(76)
At September 30, 2021	**$**	**15,251**	**$**	**15,251**	**$**	**30,502**
Accumulated amortization:						
At December 31, 2019	$	965	$	1,608	$	2,573
Depreciation		3,227		5,378		8,605
Foreign translation impact		(196)		(326)		(522)
At December 31, 2020	**$**	**3,996**	**$**	**6,660**	**$**	**10,656**
Depreciation		2,246		3,743		5,989
Foreign translation impact		26		43		69
At September 30, 2021	**$**	**6,268**	**$**	**10,446**	**$**	**16,714**
Net book value						
At December 31, 2020	$	11,293	$	8,629	$	19,922
At September 30, 2021	**$**	**8,983**	**$**	**4,805**	**$**	**13,788**

9. ACCOUNTS PAYABLE AND OTHER LIABILITIES

		September 30, 2021		December 31, 2020
Accounts payable	$	35,782	$	102,566
Accrued liabilities		2,009		31,754
Due to related parties (Note 13)		6,922		9,063
	$	44,713	$	143,383

10. SHARE CAPITAL

Authorized share capital

Unlimited number of common shares without par value
Unlimited number of preferred shares without par value

Common shares

During the nine months ended September 30, 2021:

There was no share capital activity during the nine months ended September 30, 2021.

During the year ended December 31, 2020:

On April 6, 2020, the Company issued 50,000 common shares to a related party pursuant to the exercise of 50,000 stock options with a weighted average exercise price of $0.30 per share for proceeds of $15,000. This was a non-cash transaction and was deducted from accrued interest on a promissory note payable to the related party.

On May 27, 2020, the Company issued 5,040,000 units for gross proceeds of $2,116,800, net $1,968,624 after a cash payment of commissions totaling $148,176. Each unit consists of one common share and one-half warrant. The Company issued a total of 352,800 brokers warrants exercisable to purchase one common share at $0.42 per share for 18 months from closing to registered investment dealers in connection with the offering. The brokers warrants totaled 7% of the total units issued and the fair value of these warrants were determined to be $121,606 (Note 12).

On July 28, 2020, the Company issued 300,000 common shares pursuant to the exercise of 300,000 stock options with a weighted average exercise price of $0.30 per share for proceeds of $90,000. In connection with the exercise, an amount of $37,890 was reclassified from reserves to share capital.

On September 28, 2020, the Company closed a shares for debt transaction where 536,455 common shares were issued with a fair value of $0.40 per share to a creditor for settlement of $133,784 (USD$100,000) of a convertible promissory note and accrued interest of $28,442 (USD$21,260).

During the year ended December 31, 2020, the Company issued 213,750 common shares pursuant to the exercise of 213,750 warrants with a weighted average exercise price of $0.45 per share for proceeds of $96,188.

Escrowed shares

In accordance with National Policy 46-201 - Escrow for Initial Public Offerings, all securities an issuer owned or controlled by its principals are required to be placed in escrow at the time of the issuer's initial public offering, unless the shares held by the principal or issuable to the principal upon conversion of convertible securities held by the principal collectively represent less than 1% of the voting rights attaching to the total issued and outstanding securities of the issuer after giving effect to the initial public offering. Upon completion of the Offering, the Company became an "emerging issuer" as defined in NP 46-201.

(Expressed in Canadian dollars)

10. SHARE CAPITAL (continued)

8,387,501 common shares (the "Escrowed Securities") are held by, and are subject to the terms of an escrow agreement dated April 10, 2018 and the holders of the Escrowed Securities. The shares are subject to Escrow with the following release dates.

On the Listing Date	1/10 of the Escrowed Securities
6 months after the Listing Date	1/6 of the remaining Escrowed Securities
12 months after the Listing Date	1/5 of the remaining Escrowed Securities
18 months after the Listing Date	1/4 of the remaining Escrowed Securities
24 months after the Listing Date	1/3 of the remaining Escrowed Securities
30 months after the Listing Date	1/2 of the remaining Escrowed Securities
36 months after the Listing Date	the remaining Escrowed Securities

As at September 30, 2021, 1,258,125 common shares remained in escrow.

11. RESERVES

Stock option plan
The Directors of the Company adopted a stock option plan on April 10, 2018 (the "Plan"). The Plan provides that, subject to the requirements of the Canadian Securities Exchange, the aggregate number of securities reserved for issuance will be 10% of the number of the Company's Common Shares issued and outstanding at the time such options are granted. The Plan provides that the number of Common Shares that may be reserved for issuance to any one individual upon exercise of all stock options held by such individual may not exceed 5% of the issued Common Shares, if the individual is a director, officer, employee or consultant, or 1% of the issued Common Shares, if the individual is engaged in providing investor relations services, on a yearly basis.

All options granted under the Plan will expire not later than the date that is ten years from the date that such options are granted. Options terminate earlier as follows: (i) immediately in the event of dismissal with cause; (ii) 90 days from date of termination other than for cause; or (iii) one year from the date of death or disability.

Stock options

During the nine months ended September 30, 2021, there were no stock options granted.

During the year ended December 31, 2020:

On February 1, 2020 the Company granted 100,000 stock options to a consultant of the Company. These options entitle the holder to acquire common shares of the Company at $0.30 per share, vesting immediately on grant, and expire on February 1, 2022.

On March 25, 2020, the Company granted 50,000 stock options to a consultant of the Company. These options entitle the holder to acquire common shares of the Company at $0.35 per share, vesting immediately on grant, and expire on March 25, 2022.

On April 10, 2020, a total of 1,050,000 stock options with an exercise price of $0.30 expired.

On April 13, 2020, the Company granted 1,100,000 stock options to members of key management. These options entitle the holder to acquire common shares of the Company at $0.41 per share, vesting immediately on grant, and expire on April 13, 2022.

(Expressed in Canadian dollars)

11. RESERVES (Continued)

On June 1, 2020, the Company granted 200,000 stock options to a consultant. These options entitle the holder to acquire common shares of the Company at $0.41 per share, vesting immediately on grant, and expire on June 1, 2021.

On November 12, 2020, the Company granted 175,000 stock options to consultants of the Company. These options entitle the holder to acquire common shares of the Company at $0.37 per share, vesting immediately on grant, and expire on November 12, 2022.

The stock options were valued using the Black Scholes Option Pricing model using the following weighted average assumptions: share price: $0.40 expected life: 1.88 years, expected volatility: 128%, dividend yield: 0%, risk-free interest rate: 0.38%. Expected volatility is based on historical price volatility to the extent of the expected life of the option.

Share-based compensation expense for the stock options that vested during the year ended December 31, 2020 was $413,022.

A summary of stock option activity for the nine months ended September 30, 2021 is as follows:

	Options		Weighted average exercise price
Outstanding, December 31, 2019	1,750,000	$	0.30
Granted	1,625,000		0.41
Exercised	(350,000)		0.30
Expired	(1,100,000)		0.30
Outstanding, December 31, 2020	1,925,000	$	0.30
Expired	(250,000)		0.47
Outstanding and exercisable, September 30, 2021	**1,675,000**	**$**	**0.38**

As at September 30, 2021, the following stock options were outstanding and exercisable:

Numbers of options	Exercise price	Expiry date
300,000	0.30	October 8, 2021
100,000	0.30	February 1, 2022
1,100,000	0.41	April 13, 2022
175,000	0.37	November 12, 2022
1,675,000		

At September 30 2021, the weighted-average remaining contractual life of options outstanding is 0.49 years (September 30, 2020 – 1.38 years).

Warrants

During the nine months ended September 30, 2021, there was no warrant activity.

During the year ended December 31, 2020:

In connection to the private placement that closed on May 27, 2020, the Company issued a total of 352,800 brokers warrants exercisable to purchase one common share at $0.60 per share.

(Expressed in Canadian dollars)

11. RESERVES (Continued)

The brokers warrants were valued using the Black Scholes Option Pricing model using the following weighted average assumptions: share price: $0.52, expected life: 1.50 years, expected volatility: 164%, dividend yield: 0%, risk-free interest rate: 0.28%. Expected volatility is based on historical price volatility to the extent of the expected life of the warrants. The fair value of the brokers warrants was $121,606.

A summary of warrant activity for the nine months ended September 30, 2021 is as follows:

	Warrants		Weighted average exercise price
Outstanding, December 31, 2019	4,647,490	$	0.45
Issued	2,872,800		0.60
Exercised	(213,750)		0.45
Expired	(4,433,740)		0.45
Outstanding and exercisable, December 31, 2020 and September 30, 2021	**2,872,800**	**$**	**0.60**

As at September 30, 2021, the following warrants were outstanding:

Numbers of warrants		Exercise price	Expiry date
2,872,800	$	0.60	November 26, 2021
2,872,800	**$**	**0.60**	

As at September 30, 2021, the weighted-average remaining contractual life of warrants outstanding is 0.16 years (September 30, 2020 – 0.53 years).

12. SEGMENTED INFORMATION

The Company primarily operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare®, a patented polymer-based technology for topical and transdermal skin care products as well as the sale of DermSafe hand sanitizer, the Company's first non-cannabis product. As the operations comprise a single reporting segment, amounts disclosed in the financial statements also represent segment amounts.

The operating segment of the Company is defined as a component of the Company for which separate financial information is available and is evaluated regularly by the chief operating decision maker in allocating resources and assessing performance. The chief operating decision maker of the Company is the Chief Executive Officer.

The Company has one group of similar products due to having a similar underlying technology, class of customers, and economic characteristics.

Revenue

		September 30, 2021		September 30, 2020
Canada	$	41,347	$	128,433
United States		108,229		245,831
Asia		-		130,110
United Kingdom		-		56,725
Mexico		35,115		52,058
	$	184,691	$	613,157

(Expressed in Canadian dollars)

12. SEGMENTED INFORMATION (Continued)

Total Long-Lived Assets

	September 30, 2021	December 31, 2020
United States	$ 755,782	$ 761,917
	$ 755,782	$ 761,917

The majority of the revenue earned in the United States of America are generated from one major customer.

13. RELATED PARTY TRANSANCTIONS

Key management compensation

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers. The remuneration of directors and key management personnel is as follows:

	September 30, 2021	September 30, 2020
Management fees	$ 265,050	$ 279,252
Director fees	6,000	6,000
	$ 271,050	$ 285,252

Related party transactions and balances

As at September 30, 2021, trade and other payables consists of $6,922 (December 31, 2020 - $9,063) in directors fees, royalties, consulting fees, expense reimbursements, and rent expense owed to related parties. These amounts are non-interest bearing, unsecured and due on demand.

During the three and nine months ended September 30, 2021, the Company paid or accrued $3,000 and $9,000 respectively (2020 - $3,000 and $9,000) in consulting fees to a Company owned by the CFO's spouse. As at September 30, 2021, the Company owed $1,050 (December 31, 2020 - $l,050) to this related party.

During the three and nine months ended September 30, 2021 the Company paid or accrued $6,000 and $18,000 respectively (2020 - $6,000 and 18,000) in rent expenses to a Company controlled by a director and CFO of the Company. As at September 30, 2021, the Company owed $3,150 (December 31, 2020 - $3,150) to this related party.

During the three and nine months ended September 30, 2021, the Company paid or accrued $nil and $nil respectively (2020 - $18,239 and $62,605) in rent expense, and $60 and $3,181 respectively (2020 - $8,789 and $18,944) in royalties to a Company with a common CEO and director. As at September 30, 2021, the Company owed $nil (December 31, 2020 - $2,339 to this related party.

14. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern in order to pursue its operations and to maintain a flexible capital structure, which optimizes the costs of capital at an acceptable risk. The Company considers its capital for this purpose to be its promissory notes, convertible notes and shareholders' equity.

14. CAPITAL MANAGEMENT (Continued)

The Company's primary source of capital is through the issuance of convertible notes and equity. The Company manages and adjusts its capital structure when changes in economic conditions occur. To maintain or adjust the capital structure, the Company may seek additional funding. The Company may require additional capital resources to meet its administrative overhead expenses in the long term. The Company believes it will be able to raise capital as required in the long term but recognizes there will be risks involved that may be beyond its control. There are no external restrictions on the management of capital.